Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 15/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL111598 | 0.98 | ROCK2 (0.45) | ROCK2ROCK1RIOK2IMPDH2AR | |
| SCHEMBL31370526 | 0.86 | AKR1C3 (0.58) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL1492894 | 0.86 | AKR1C3 (0.58) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL16634905 | 0.81 | ROCK2 (0.52) | ROCK2ROCK1MYLK4 | |
| SCHEMBL30564493 | 0.79 | AKR1C3 (0.54) | — | |
| SCHEMBL1492665 | 0.79 | APP (0.45) | ROCK2RIOK2IMPDH2 | |
| SCHEMBL1137612 | 0.78 | UGT2B7 (0.58) | — | |
| SCHEMBL3128980 | 0.78 | UGT2B7 (0.58) | ROCK2ROCK1IMPDH2 | |
| SCHEMBL13877544 | 0.78 | ROCK2 (0.43) | ROCK2ROCK1IMPDH2MYLK4 | |
| SCHEMBL29941609 | 0.78 | UGT2B7 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-11197853-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210236477-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2021-08-05 | — | — | US | disclosed |
| US-11020385-B2 | Combination therapy | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200129498-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618748-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885RIOK2 791/4885 |
| US-11020385-B2 | Combination therapy | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885RIOK2 2951/4885 |
| US-20210236477-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885RIOK2 2951/4885 |
| US-20200129498-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885RIOK2 2951/4885 |
| US-11197853-B2 | Combination therapy | PTGS1, PTGS2, PTGIS | ROCK2 110/4885ROCK1 159/4885RIOK2 2951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.